PURE Bioscience (OTCMKTS: PURE) is one of 256 public companies in the “MED PRODS” industry, but how does it weigh in compared to its rivals? We will compare PURE Bioscience to similar businesses based on the strength of its analyst recommendations, dividends, risk, earnings, profitability, institutional ownership and valuation.
This table compares PURE Bioscience and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|PURE Bioscience Competitors||-649.47%||-97.76%||-13.44%|
This table compares PURE Bioscience and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|PURE Bioscience||$1.83 million||-$6.26 million||-5.00|
|PURE Bioscience Competitors||$3.73 billion||$128.99 million||-3.16|
PURE Bioscience’s rivals have higher revenue and earnings than PURE Bioscience. PURE Bioscience is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of current ratings and target prices for PURE Bioscience and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|PURE Bioscience Competitors||1080||4484||8386||268||2.55|
As a group, “MED PRODS” companies have a potential upside of 8.46%. Given PURE Bioscience’s rivals higher probable upside, analysts plainly believe PURE Bioscience has less favorable growth aspects than its rivals.
Institutional and Insider Ownership
0.2% of PURE Bioscience shares are held by institutional investors. Comparatively, 52.5% of shares of all “MED PRODS” companies are held by institutional investors. 10.6% of PURE Bioscience shares are held by insiders. Comparatively, 15.4% of shares of all “MED PRODS” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
PURE Bioscience has a beta of -1.55, suggesting that its share price is 255% less volatile than the S&P 500. Comparatively, PURE Bioscience’s rivals have a beta of 0.96, suggesting that their average share price is 4% less volatile than the S&P 500.
PURE Bioscience rivals beat PURE Bioscience on 8 of the 9 factors compared.
PURE Bioscience Company Profile
PURE Bioscience, Inc. is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC). It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains and food processors. It is testing and continuing development of PURE Control to utilize PURE Control as a direct food contact processing aid for raw meats, including beef and pork. In addition to PURE Hard Surface and PURE Control, it manufactures and sells SDC-based products for end use; products preserved with SDC, and SDC as a raw material ingredient for manufacturing use. These products include PURE Multi-Purpose and Floor Cleaner Concentrate, PURE Multi-Purpose Hi-Foam Cleaner Concentrate, Axen 30, Axenohl and SILVERION.
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.